2023 CANADIAN CARDIOVASCULAR SOCIETY / CANADIAN ASSOCIATION OF INTERVENTIONAL CARDIOLOGY FOCUSED UPDATE OF THE GUIDELINES FOR THE USE OF ANTIPLATELET THERAPY / SOCIÉTÉ CARDIOVASCULAIRE DU CANADA 2023 / ASSOCIATION CANADIENNE DE CARDIOLOGIE D'INTERVENTION : MISE À JOUR DES LIGNES DIRECTRICES POUR L'UTILISATION DE LA THÉRAPIE ANTIPLAQUETTAIRE (CCC-177)

Saturday, October 28, 2023

15:15 – 16:15 EST

Location: Palais, 513ABC

Target Audience: General: All cardiovascular (clinical and research) health professionals, Structural Interventional Team Members, Primary Care Physicians

Co-Chair(s)

Kevin R. Bainey, MD

Interventional Cardiologist
University of Alberta Hospital
University of Alberta
Guillaume Marquis-Gravel, MD, MSc

Interventional Cardiologist, Assistant Professor of Medicine
Montreal Heart Institute, Université de Montréal
Institut de Cardiologie de Montréal

Presenter(s)

David J. Bewick, MD, FRCPC

Associate Professor
New Brunswick Heart Center
Dalhousie University
Laurie-Anne Boivin Proulx

Interventional Cardiology Fellow
University of Ottawa Heart Institute
University of Ottawa Heart Institute
Stephen E. Fremes, MD, MSc, FRCSC

Professor of Surgery, University of Toronto, Staff Surgeon, Schulich Heart Centre, Sunnybrook HSC
Sunnybrook HSC, University of Toronto
Marie Lordkipanidzé, PharmD

Principal Investigator
University of Montreal, Montreal Heart Institute
Faculté de pharmacie, Université de Montréal
Samer Mansour (he/him/his)

MD
CAIC
CHUM
Shamir R. Mehta, MD, MSc

Douglas Holder PHRI Endowed Chair in Interventional Cardiology Professor of Medicine, McMaster University Director, Interventional Cardiology Hamilton Health Sciences Senior Scientist, Population Health Research Institute
McMaster University
McMaster Unviersity
Jean-François Tanguay, MD, FRCPC, FCCS, FACC, FAHA, FESC

Director, Interventional Cardiology Division, Montreal Heart Insitute,
University of Montreal
Université de Montréal
Robert C. Welsh, MD

Professor of Medicine
Mazankowski Alberta Heart Institute
University of Alberta

Planning Committee Member(s)

David J. Bewick, MD, FRCPC

Associate Professor
New Brunswick Heart Center
Dalhousie University
Emilie P. Belley-Cote, MD

EARLY CAREER
CCS, CANCARE
McMaster Unviersity
CG

Carol A. Geller

Family Physician

Disclosure(s):

Guillaume Marquis-Gravel, MD, MSc: Bayer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, December 7, 2021), Speaker/Honoraria (Terminated, December 7, 2021); Boston Scientific: Consultant/Advisory Board (Terminated, May 12, 2022), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, May 12, 2022); CSI: Speaker/Honoraria (Terminated, April 26, 2022); HLS Therapeutics: Consultant/Advisory Board (Terminated); JAMP Pharma: Consultant/Advisory Board (Terminated, January 13, 2022), Speaker/Honoraria (Terminated, January 13, 2022); KYE: Consultant/Advisory Board (Terminated, May 11, 2022), Speaker/Honoraria (Terminated, May 11, 2022); Novartis: Consultant/Advisory Board (Terminated, March 22, 2023), Speaker/Honoraria (Terminated, March 22, 2023); Pharmascience: Consultant/Advisory Board (Terminated, April 14, 2022), Speaker/Honoraria (Terminated, April 14, 2022); Servier: Consultant/Advisory Board (Terminated, October 23, 2019)

Kevin R. Bainey, MD: No financial relationships to disclose

David J. Bewick, MD, FRCPC: No financial relationships to disclose

Laurie-Anne Boivin Proulx: No financial relationships to disclose

Stephen E. Fremes, MD, MSc, FRCSC: Amgen Inc: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Boston Scientific: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); CIHR: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Medtronic: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); NIH: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Polypid: Consultant/Advisory Board (Ongoing)

Marie Lordkipanidzé, PharmD: JAMP Pharma: Consultant/Advisory Board (Terminated, October 31, 2022); Servier: Consultant/Advisory Board (Terminated, October 31, 2021); Stago: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing)

Samer Mansour: Abbott vascular: Consultant/Advisory Board (Terminated, April 2, 2023), Speaker/Honoraria (Terminated, April 2, 2023); Amgen: Consultant/Advisory Board (Terminated, April 2, 2023); Bayer: Speaker/Honoraria (Ongoing); Bohringer Ingelheim: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); HLS: Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Terminated, April 2, 2023), Speaker/Honoraria (Terminated, April 2, 2023); Sanofi: Consultant/Advisory Board (Terminated, April 2, 2023), Speaker/Honoraria (Terminated, April 2, 2023)

Shamir R. Mehta, MD, MSc: Abbott: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Amgen: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Janssen: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Jean-François Tanguay, MD, FRCPC, FCCS, FACC, FAHA, FESC: Abbott Vascular: Consultant/Advisory Board (Ongoing), Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Biosensors: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); HLS: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); JAMP Pharma: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Novartis: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing)

Robert C. Welsh, MD: Astra Zeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Bayer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Bristol Myers: Consultant/Advisory Board (Ongoing); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing)

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

prescribe antiplatelet agents in both primary and secondary prevention according to the best updated evidence, including in patients undergoing PCI;
prescribe antiplatelet agents based on the best evidence in the vulnerable populations of patients with ACS treated medically without PCI, and in patients at high bleeding risk (HBR) undergoing PCI (including patients on oral anticoagulants for atrial fibrillation); and
prescribe antiplatelet agents based on the best evidence in patients undergoing CABG.

Workshop Description: In this session, the 2023 Canadian Cardiovascular Society / Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy will be presented. Topics covered will include: aspirin in primary prevention of atherosclerotic cardiovascular disease, DAPT duration after PCI in patients at high risk of bleeding, DAPT pre-treatment before PCI, antithrombotic management of patients with AF and ACS, antiplatelet de-escalation after PCI, DAPT after CABG, and DAPT in patients with ACS treated without revascularization.